Need help finding what you are looking for?
Contact Us
PUBLISHER: Transparency Market Research | PRODUCT CODE: 1101519
PUBLISHER: Transparency Market Research | PRODUCT CODE: 1101519
Meningococcal Vaccines Market (Type: Polysaccharide, Conjugate Vaccines, Combination Vaccines, Men B Vaccine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
PUBLISHED:
PAGES: 189 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
The report provides revenue of the global meningococcal vaccines market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global meningococcal vaccines market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the meningococcal vaccines market.
The report delves into the competitive landscape of the global meningococcal vaccines market. Key players operating in the global meningococcal vaccines market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global meningococcal vaccines market profiled in this report.
Product Code: TMRGL1666
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Meningococcal Vaccines Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2021-2031
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Regulatory Scenario by Region/globally
- 5.3. Covid-19 Impact analysis
6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 6.3.1. Polysaccharide
- 6.3.1.1. Menomune
- 6.3.1.2. Mencevax
- 6.3.1.3. NmVac4
- 6.3.1.4. Others
- 6.3.2. Conjugate Vaccines
- 6.3.2.1. Menactra
- 6.3.2.2. Menveo
- 6.3.2.3. NeisVac-C
- 6.3.2.4. Nimenrix
- 6.3.2.5. Others
- 6.3.3. Combination Vaccines
- 6.3.3.1. MenHibrix
- 6.3.3.2. Menitorix
- 6.3.4. Men B Vaccines
- 6.3.4.1. Bexsero
- 6.3.4.2. Trumenba
- 6.3.1. Polysaccharide
- 6.4. Global Meningococcal Vaccines Market Attractiveness, by Type
7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 7.3.1. Retail Pharmacies
- 7.3.2. Hospital Pharmacies
- 7.3.3. Others (online pharmacies, drug stores)
- 7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user
8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Global Meningococcal Vaccines Market Value Forecast, by Region
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Global Meningococcal Vaccines Market Attractiveness, by Country/Region
9. North America Meningococcal Vaccines Market Analysis and Forecast
- 9.1. Introduction
- 9.1.1. Key Findings
- 9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 9.2.1. Polysaccharide
- 9.2.1.1. Menomune
- 9.2.1.2. Mencevax
- 9.2.1.3. NmVac4
- 9.2.1.4. Others
- 9.2.2. Conjugate Vaccines
- 9.2.2.1. Menactra
- 9.2.2.2. Menveo
- 9.2.2.3. NeisVac-C
- 9.2.2.4. Nimenrix
- 9.2.2.5. Others
- 9.2.3. Combination Vaccines
- 9.2.3.1. MenHibrix
- 9.2.3.2. Menitorix
- 9.2.4. Men B Vaccines
- 9.2.4.1. Bexsero
- 9.2.4.2. Trumenba
- 9.2.1. Polysaccharide
- 9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 9.3.1. Retail Pharmacies
- 9.3.2. Hospital Pharmacies
- 9.3.3. Others (online pharmacies, drug stores)
- 9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2021-2031
- 9.4.1. U.S.
- 9.4.2. Canada
- 9.5. North America Meningococcal Vaccines Market Attractiveness Analysis
- 9.5.1. By Type
- 9.5.2. By End-user
- 9.5.3. By Country
10. Europe Meningococcal Vaccines Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Key Findings
- 10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 10.2.1. Polysaccharide
- 10.2.1.1. Menomune
- 10.2.1.2. Mencevax
- 10.2.1.3. NmVac4
- 10.2.1.4. Others
- 10.2.2. Conjugate Vaccines
- 10.2.2.1. Menactra
- 10.2.2.2. Menveo
- 10.2.2.3. NeisVac-C
- 10.2.2.4. Nimenrix
- 10.2.2.5. Others
- 10.2.3. Combination Vaccines
- 10.2.3.1. MenHibrix
- 10.2.3.2. Menitorix
- 10.2.4. Men B Vaccines
- 10.2.4.1. Bexsero
- 10.2.4.2. Trumenba
- 10.2.1. Polysaccharide
- 10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 10.3.1. Retail Pharmacies
- 10.3.2. Hospital Pharmacies
- 10.3.3. Others (online pharmacies, drug stores)
- 10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Italy
- 10.4.5. Spain
- 10.4.6. Rest of Europe
- 10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis
- 10.5.1. By Type
- 10.5.2. By End-user
- 10.5.3. By Country/Sub-region
11. Asia Pacific Meningococcal Vaccines Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 11.2.1. Polysaccharide
- 11.2.1.1. Menomune
- 11.2.1.2. Mencevax
- 11.2.1.3. NmVac4
- 11.2.1.4. Others
- 11.2.2. Conjugate Vaccines
- 11.2.2.1. Menactra
- 11.2.2.2. Menveo
- 11.2.2.3. NeisVac-C
- 11.2.2.4. Nimenrix
- 11.2.2.5. Others
- 11.2.3. Combination Vaccines
- 11.2.3.1. MenHibrix
- 11.2.3.2. Menitorix
- 11.2.4. Men B Vaccines
- 11.2.4.1. Bexsero
- 11.2.4.2. Trumenba
- 11.2.1. Polysaccharide
- 11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 11.3.1. Retail Pharmacies
- 11.3.2. Hospital Pharmacies
- 11.3.3. Others (online pharmacies, drug stores)
- 11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
- 11.4.1. China
- 11.4.2. Japan
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of Asia Pacific
- 11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis
- 11.5.1. By Type
- 11.5.2. By End-user
- 11.5.3. By Country/Sub-region
12. Latin America Meningococcal Vaccines Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 12.2.1. Polysaccharide
- 12.2.1.1. Menomune
- 12.2.1.2. Mencevax
- 12.2.1.3. NmVac4
- 12.2.1.4. Others
- 12.2.2. Conjugate Vaccines
- 12.2.2.1. Menactra
- 12.2.2.2. Menveo
- 12.2.2.3. NeisVac-C
- 12.2.2.4. Nimenrix
- 12.2.2.5. Others
- 12.2.3. Combination Vaccines
- 12.2.3.1. MenHibrix
- 12.2.3.2. Menitorix
- 12.2.4. Men B Vaccines
- 12.2.4.1. Bexsero
- 12.2.4.2. Trumenba
- 12.2.1. Polysaccharide
- 12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 12.3.1. Retail Pharmacies
- 12.3.2. Hospital Pharmacies
- 12.3.3. Others (online pharmacies, drug stores)
- 12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of Latin America
- 12.5. Latin America Meningococcal Vaccines Market Attractiveness Analysis
- 12.5.1. By Type
- 12.5.2. By End-user
- 12.5.3. By Country/Sub-region
13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2021-2031
- 13.2.1. Polysaccharide
- 13.2.1.1. Menomune
- 13.2.1.2. Mencevax
- 13.2.1.3. NmVac4
- 13.2.1.4. Others
- 13.2.2. Conjugate Vaccines
- 13.2.2.1. Menactra
- 13.2.2.2. Menveo
- 13.2.2.3. NeisVac-C
- 13.2.2.4. Nimenrix
- 13.2.2.5. Others
- 13.2.3. Combination Vaccines
- 13.2.3.1. MenHibrix
- 13.2.3.2. Menitorix
- 13.2.4. Men B Vaccines
- 13.2.4.1. Bexsero
- 13.2.4.2. Trumenba
- 13.2.1. Polysaccharide
- 13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2021-2031
- 13.3.1. Retail Pharmacies
- 13.3.2. Hospital Pharmacies
- 13.3.3. Others (online pharmacies, drug stores)
- 13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of Middle East & Africa
- 13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis
- 13.5.1. By Type
- 13.5.2. By End-user
- 13.5.3. By Country/Sub-region
14. Competition Landscape
- 14.1. Market Player - Competition Matrix (by tier and size of companies)
- 14.2. Market Share Analysis, by Company, 2021
- 14.3. Company Profiles
- 14.3.1. Sanofi SA
- 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.1.2. Product Portfolio
- 14.3.1.3. SWOT Analysis
- 14.3.1.4. Strategic Overview
- 14.3.2. Novartis International
- 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.2.2. Product Portfolio
- 14.3.2.3. SWOT Analysis
- 14.3.2.4. Strategic Overview
- 14.3.3. GlaxoSmithKline plc
- 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.3.2. Product Portfolio
- 14.3.3.3. SWOT Analysis
- 14.3.3.4. Strategic Overview
- 14.3.4. Pfizer Inc.
- 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.4.2. Product Portfolio
- 14.3.4.3. SWOT Analysis
- 14.3.4.4. Strategic Overview
- 14.3.5. Nuron Biotech.
- 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.5.2. Product Portfolio
- 14.3.5.3. SWOT Analysis
- 14.3.5.4. Strategic Overview
- 14.3.6. JN-International Medical Corporation.
- 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.6.2. Product Portfolio
- 14.3.6.3. SWOT Analysis
- 14.3.6.4. Strategic Overview
- 14.3.7. Serum Institute of India Ltd
- 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.7.2. Product Portfolio
- 14.3.7.3. SWOT Analysis
- 14.3.7.4. Strategic Overview
- 14.3.8. Baxter International
- 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.8.2. Product Portfolio
- 14.3.8.3. SWOT Analysis
- 14.3.8.4. Strategic Overview
- 14.3.1. Sanofi SA
Product Code: TMRGL1666
List of Tables
- Table 01: Global Meningococcal Vaccine Market Pipeline Analysis
- Table 02: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
- Table 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide Meningococcal Vaccines, 2022-2031
- Table 04: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Meningococcal Vaccines, 2022-2031
- Table 05: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Meningococcal Vaccines, 2022-2031
- Table 06: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Meningococcal Vaccines, 2022-2031
- Table 07: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
- Table 08: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Region, 2022-2031
- Table 09: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country, 2022-2031
- Table 10: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
- Table 11: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
- Table 12: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
- Table 13: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
- Table 14: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
- Table 15: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
- Table 16: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022-2031
- Table 17: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
- Table 18: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
- Table 19: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
- Table 20: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
- Table 21: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
- Table 22: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
- Table 23: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022-2031
- Table 24: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
- Table 25: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
- Table 26: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
- Table 27: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
- Table 28: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
- Table 29: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
- Table 30: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022-2031
- Table 31: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
- Table 32: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
- Table 33: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
- Table 34: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
- Table 35: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
- Table 36: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
- Table 37: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022-2031
- Table 38: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022-2031
- Table 39: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022-2031
- Table 40: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022-2031
- Table 41: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022-2031
- Table 42: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022-2031
- Table 43: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022-2031
List of Figures
- Figure 01: Global Meningococcal Vaccines Market Size (US$ Bn) and Distribution, by Region, 2022 and 2031
- Figure 02: Market Snapshot of Global Meningococcal Vaccines Market
- Figure 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
- Figure 04: Market Value Share, by Type, 2021
- Figure 05: Market Value Share, by End-user, 2021
- Figure 06: Market Value Share, by Region, 2021
- Figure 07: Global Meningococcal Vaccines Market Value Share Analysis, by Type, 2022 and 2031
- Figure 08: Global Meningococcal Vaccines Market Attractiveness, by Type2022-2031
- Figure 09: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Polysaccharide Vaccines, 2022-2031
- Figure 10: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Conjugate Vaccines, 2022-2031
- Figure 11: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, Combination Vaccines, 2022-2031
- Figure 12: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Men B Vaccines, 2021
- Figure 13: Global Meningococcal Vaccines Market Value Share Analysis, by End-user, 2022 and 2031
- Figure 14: Global Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
- Figure 15: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2022-2031
- Figure 16: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2022-2031
- Figure 17: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022-2031
- Figure 18: Global Meningococcal Vaccines Market Value Share (%), by Region, 2022 and 2031
- Figure 19: Global Meningococcal Vaccines Market Attractiveness, by Region2022-2031
- Figure 20: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
- Figure 21: North America Meningococcal Vaccines Market Value Share (%), by Country, 2022 and 2031
- Figure 22: North America Meningococcal Vaccines Market Attractiveness, by Country2022-2031
- Figure 23: North America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
- Figure 24: North America Meningococcal Vaccines Market Attractiveness, by Type2022-2031
- Figure 25: North America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
- Figure 26: North America Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
- Figure 27: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
- Figure 28: Europe Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
- Figure 29: Europe Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022-2031
- Figure 30: Europe Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
- Figure 31: Europe Meningococcal Vaccines Market Attractiveness, by Type2022-2031
- Figure 32: Europe Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
- Figure 33: Europe Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
- Figure 34: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
- Figure 35: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
- Figure 36: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022-2031
- Figure 37: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
- Figure 38: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Type2022-2031
- Figure 39: Asia Pacific Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
- Figure 40: Asia Pacific Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
- Figure 41: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
- Figure 42: Latin America Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
- Figure 43: Latin America Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022-2031
- Figure 44: Latin America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
- Figure 45: Latin America Meningococcal Vaccines Market Attractiveness, by Type2022-2031
- Figure 46: Latin America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
- Figure 47: Latin America Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
- Figure 48: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022-2031
- Figure 49: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
- Figure 50: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022-2031
- Figure 51: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
- Figure 52: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Type2022-2031
- Figure 53: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
- Figure 54: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by End-user2022-2031
- Figure 55: Global Meningococcal Vaccines Market Share, by Company, 2018
- Figure 56: Baxter International, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016-2018
- Figure 57: Baxter International, Inc. Breakdown of Net Sales (%), by Region, 2018
- Figure 58: Pfizer Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016-2018
- Figure 59: Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018
- Figure 60: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2014-2021
- Figure 61: Novartis AG Breakdown of Net Sales, by Region, 2021
- Figure 62: Novartis AG Breakdown of Net Sales, by Business Segment, 2021
- Figure 63: Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2021
- Figure 64: Sanofi S.A Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2021
- Figure 65: Sanofi S.A Breakdown of Net Sales (%), by Business Segment, 2021
- Figure 66: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2021
- Figure 67: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2021
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.